Observational Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8186-8195
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8186
Table 1 Demographic and clinical characteristics

Survival group (n = 157)
Death group (n = 50)
P value
Age (yr)40 (32, 48)51(39, 55)0.000
Gender (male, %)130/157, 82.842/50, 84.00.844
Classification of liver failure (%)0.006
A116/157, 73.8929/50, 58.00
B92/157, 58.6016/50, 32.00
C2/157, 1.275/50, 10.00
Stage of liver failure (%)0.000
Early 101/157, 64.335/50, 10.00
Middle42/157, 26.7513/50, 26.00
Late14/157, 8.9232/50, 64.00
Complications (%)
Pulmonary infection39/157, 24.8424/50, 48.000.003
Hepatic encephalopathy10/157, 6.3723/50, 46.000.000
Spontaneous bacterial peritonitis10/157, 6.3711/50, 22.000.005
Hepatorenal syndrome0/157, 04/50, 8.000.003
Upper gastrointestinal hemorrhage2/157, 1.276/50, 12.000.003
PLT (109/L)128 (102, 154.50)103 (87.50, 153)0.044
ALB (g/dL)3.28 ± 0.503.21 ± 0.530.381
Tbil (mg/dL)13.55 (9.59, 19.88)17.19 (12.36, 25.65)0.011
ALT (U/L)948.50 (400, 1984.7)838.8 (331.40, 1705.78)0.626
AST (U/L)687.90 (273.85, 1258.50)721.50 (252.50, 1554.35)0.800
CHE (U/L)4359 (3288, 5429)3898 (2786.75, 5029.50)0.197
Glu (mmol/L)4.26 (3.65, 5.23)4.64 (3.73, 5.75)0.276
BUN (mg/dL)9.08 (7.21, 12.30)10.97 (8.42, 15.16)0.014
Cr (mg/dL)0.73 (0.61, 0.84)0.76 (0.62, 0.94)0.309
Na (mmol/L)136.30 (134.30, 138.00)135.22 (132.48, 138.33)0.172
NLR2.66 (1.89, 4.05)4.00 (2.42, 6.43)0.000
INR1.83 (1.65, 2.13)2.23 (1.93, 3.18)0.000
HBsAg (log10IU/L)3.70 (3.31, 3.91)3.23 (2.65, 3.74)0.001
HBeAg positive (%)89/157 (56.70)16/50 (32.00)0.002
HBV-DNA (log10IU/L)6.34 (5.14, 7.46)6.39 (4.87, 7.82)0.698
AFP (ng/mL) 63.15 (15.35, 204)16.18 (6.79, 48.33)0.000
GP73 (ng/mL)237.92 (208.84, 309.79)305.83 (215.32, 366.49)0.003